Imatinib Completed Phase 1 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00354068Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
NCT00401024Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
NCT00387933Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma